MDXG

MIMEDX Announces First Quarter 2026 Operating & Financial Results

MDXG Reports Q1 Sales Drop and Lowers 2026 Revenue Forecast

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>MiMedx Group, Inc. (MDXG) posted a Q1 2026 net sales of $59 million, a 33% decline due to significant disruptions in the wound care sector from new Medicare reimbursement policies. Despite robust performance in surgical sales, the company lowered full-year revenue expectations to $260-$290 million but anticipates profitability through cost-cutting measures implemented this quarter. Recovery signs in wound sales could offer potential upside as the year progresses.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>MDXG reports Q1 2026 net sales of $59 million, down 33%.</li><li>Wound business declines 60% while Surgical products increase by 13%.</li><li>Adjusting 2026 sales guidance to $260-$290 million due to Medicare changes.</li><li>$40 million in cost-saving measures expected to enhance profitability.</li><li>Signs of recovery in wound product sales observed towards quarter end.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Medicare (N/A)</strong>: Recent policy changes significantly impacting wound product sales.</li><li><strong>MiMedx Group, Inc. (MDXG)</strong>: Focus on cost management to withstand current market disruptions.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>The news fits under &#039;Earnings&#039; as it involves financial performance disclosures impacting investor sentiment. The significant changes in revenue projections highlight the company&#039;s response to external challenges, warranting close evaluation from investors.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lowered 2026 revenue guidance could prompt analyst downgrades.</li><li>Cash position remains strong at $160 million, bolstering confidence.</li><li>Cost-saving initiatives may mitigate losses if wound sales recover.</li><li>Continued Medicare reimbursement challenges highlight vulnerability in revenue.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Net sales of $59 million in Q1 2026 compared to $88 million in Q1 2025.</li><li>Surgical product sales increased 13% year-over-year.</li><li>Wound business sales declined 60% due to Medicare reimbursement changes.</li><li>2026 net sales expected between $260-$290 million, down from previous forecasts.</li><li>Company holds $160 million in cash and cash equivalents as of March 31, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider short-term bearish position in MDXG anticipating continued revenue headwinds.</p>
  </section>
</section>


<article>
    <h1>MIMEDX Announces First Quarter 2026 Operating & Financial Results</h1>
    <p>MARIETTA, Ga., April 29, 2026 — MiMedx Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/MDXG">MDXG</a>), a regenerative medicine company, reported its operating and financial results for the first quarter of 2026, highlighting a net sales figure of <strong>$59 million</strong>. The company also revised its net sales and adjusted EBITDA expectations for the full fiscal year in light of recent Medicare policy changes that have affected its wound care business.</p>

    <section>
        <h2>Impact of Medicare Policy Changes</h2>
        <p>Chief Executive Officer Joseph H. Capper shared insights on the challenges faced during the quarter. He noted, <em>"The first quarter of 2026 was adversely impacted by new Medicare reimbursement policies in the advanced wound care space, which led to significant confusion across the industry."</em> The inconsistent implementation of these policies by Medicare Administrative Contractors (MACs) added further complications for both providers and patients.</p>
        
        <p>Despite the challenges, MIMEDX's Surgical business saw a <strong>13% increase</strong> year-over-year, while the Wound business experienced a staggering <strong>60% decline</strong>. Consequently, MIMEDX has adjusted its full-year net sales expectations to a range of <strong>$260 to $290 million</strong> and anticipates generating <strong>$40 million</strong> in annualized cost savings from recent adjustments to its cost structure.</p>
    </section>

    <section>
        <h2>First Quarter 2026 Financial Highlights</h2>
        <h3>Net Sales</h3>
        <p>MIMEDX's net sales for the quarter ending March 31, 2026, totaled <strong>$59 million</strong>, a <strong>33% decrease</strong> from <strong>$88 million</strong> in the same period last year. The decrease was primarily attributed to the downturn in Wound sales due to the new Medicare reimbursement changes, which include a payment cap on allowable reimbursements for skin substitutes.</p>

        <h3>Gross Profit and Margin</h3>
        <p>The gross profit for the quarter was <strong>$42 million</strong>, resulting in a gross margin of <strong>71%</strong>, compared to <strong>81%</strong> in the previous year. The decline in gross margin was mainly a direct consequence of the altered reimbursement landscape and an unfavorable product mix.</p>

        <h3>Operating Expenses</h3>
        <p>Selling, general, and administrative (SG&A) expenses were <strong>$53 million</strong> for the quarter, down from <strong>$60 million</strong> the previous year. This reduction was due to a non-recurring reversal of stock-based compensation expenses along with lower commission expenses. Research and development (R&D) expenses rose slightly to <strong>$4 million</strong>, accounting for investments in clinical trials and new product launches.</p>

        <h3>Net Income</h3>
        <p>MIMEDX reported a net loss of <strong>$11 million</strong> for the first quarter, contrasting with a net income of <strong>$7 million</strong> in the same period last year.</p>

        <h3>Cash Position</h3>
        <p>As of March 31, 2026, MIMEDX maintained <strong>$160 million</strong> in cash and cash equivalents, a minor decrease from <strong>$166 million</strong> at the end of 2025.</p>
    </section>

    <section>
        <h2>Future Outlook</h2>
        <p>For the entirety of 2026, MIMEDX now expects net sales in the range of <strong>$260 to $290 million</strong>, with adjusted EBITDA anticipated to approach breakeven. Long-term, the company aims for annual net sales growth in the low double-digits along with an adjusted EBITDA margin exceeding <strong>20%</strong>.</p>
    </section>

    <section>
        <h2>Conference Call Information</h2>
        <p>MIMEDX will hold a conference call and webcast today at <strong>4:30 PM ET</strong> to delve deeper into its first quarter results. Interested parties may join the call using the following information:</p>
        <ul>
            <li><strong>Webcast:</strong> <a href="https://www.globenewswire.com/Tracker?data=7eL8PfNG_Npke65HzjarbvF28fktCVFTrBTxukrB3R7ggxns_dj9mfAL8lV9bcSRXcOjKIQ_me4_ks-xvrwFwPRh_26VlTAoIdOHdZNWDU4xiRq_VSWRwl353YQLcaoxYPmrQs8pYuVq3jd5TI92UQ==" rel="nofollow" target="_blank"><strong><u>Click here</u></strong></a></li>
            <li><strong>U.S. Investors:</strong> 877-407-6184</li>
            <li><strong>International Investors:</strong> 201-389-0877</li>
            <li><strong>Conference ID:</strong> 13759618</li>
        </ul>
        <p>A replay will be available for a period of 30 days on the company’s website at <a href="https://www.globenewswire.com/Tracker?data=0iZR7JzoBSUV-utsME-VSEV24RFn9-rKXIhxiQjbeb80H1vu1La_gcq0JkD9ywns04o2YOKCk7GdckrhIoqooA==" rel="nofollow" target="_blank"><u>www.mimedx.com</u></a>.</p>
    </section>

    <section>
        <h2>Forward-Looking Statements</h2>
        <p>Statements in this release are forward-looking and involve risks and uncertainties regarding future financial performance and expectations. These include, but are not limited to, anticipated sales growth and adjusted EBITDA, as well as impacts from restructuring efforts and demand fluctuations in the wound segment.</p>
    </section>
</article>

MiMedx Group, Inc. (MDXG) posted a Q1 2026 net sales of $59 million, a 33% decline due to significant disruptions in the wound care sector from new Medicare reimbursement policies. Despite robust performance in surgical sales, the company lowered full-year revenue expectations to $260-$290 million but anticipates profitability through cost-cutting measures implemented this quarter. Recovery signs in wound sales could offer potential upside as the year progresses.

MIMEDX Announces First Quarter 2026 Operating & Financial Results

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Earnings

Related News